Literature DB >> 3772414

Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data.

A J Dembo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3772414     DOI: 10.1200/JCO.1986.4.11.1573

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.

Authors:  C J Gallagher; E Wiltshaw; R E Coleman; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

3.  A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.

Authors:  E M Rankin; L Mill; S B Kaye; R Atkinson; L Cassidy; J Cordiner; D Cruickshank; J Davis; I D Duncan; W Fullerton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

4.  Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.

Authors:  J A Green; H M Warenius; R D Errington; S Myint; G Spearing; A J Slater
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

5.  Extremely Late Recurrence of Ovarian Carcinoma Diagnosed by an Endoscopic Ultrasound-guided Fine-needle Biopsy.

Authors:  Mitsuru Chiba; Takashi Goto; Wataru Sato; Tomomi Shibuya; Kenichi Takahashi; Shinichiro Minami; Hisanori Matsuzawa; Yuki Sato; Katsunori Iijima
Journal:  Intern Med       Date:  2020-09-12       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.